Go Pro
OTCMKTS:NPHC

Nutra Pharma (NPHC) Stock Price, News & Analysis

Nutra Pharma logo
$0.0001 0.00 (0.00%)
As of 08/21/2026 03:58 PM Eastern

About Nutra Pharma Stock (OTCMKTS:NPHC)

Advanced

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.0001
$0.0050
Volume
65,500 shs
Average Volume
1.02 million shs
Market Capitalization
$715.97 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Nutra Pharma Corporation is a development-stage medical technology company focusing on the research and development of therapeutic products for gastrointestinal disorders, notably those arising from opioid use. The company is advancing a portfolio of proprietary formulations designed to address opioid-induced constipation (OIC), a common side effect of pain management regimens.

Its lead candidate, RIMSO-50, is an oral solution being evaluated for its potential to alleviate OIC by promoting bowel movements without compromising the effectiveness of opioid analgesics. Nutra Pharma is leveraging its in-house formulation capabilities and preclinical data to support ongoing regulatory submissions and potential partner collaborations.

Nutra Pharma holds patent protection in key jurisdictions, including the United States, Europe and Israel, covering its novel formulations and methods of use. The company’s intellectual property strategy is aimed at securing market exclusivity and facilitating potential licensing agreements.

Headquartered in Tel Aviv, Israel, Nutra Pharma is building its operational footprint with activities in North America and Europe. While the company remains in the clinical and regulatory phase, it seeks to advance its product pipeline through strategic partnerships and capital investment to bring its therapies to patients in need.

AI Generated. May Contain Errors.

Receive NPHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nutra Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NPHC Stock News Headlines

Nutra Pharma Delays Quarterly SEC Filing
Nutra Pharma Corp. (NPHC)
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
Nutra Pharma Corp (NPHC)
Nutra Pharma Corp. Reaches Settlement with SEC
Collegium Pharmaceutical
See More Headlines

NPHC Stock Analysis - Frequently Asked Questions

Nutra Pharma's stock was trading at $0.0001 at the beginning of the year. Since then, NPHC stock has increased by 0.0% and is now trading at $0.0001.

Nutra Pharma Corp. (OTCMKTS:NPHC) released its quarterly earnings data on Friday, August, 17th. The company reported $0.00 EPS for the quarter. The business earned $0.03 million during the quarter.

Shares of NPHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nutra Pharma investors own include Jumia Technologies (JMIA), Prospect Capital (PSEC), Tilray Brands (TLRY), AGNC Investment (AGNC) and Aktis Oncology (AKTS).

Company Calendar

Last Earnings
8/17/2018
Today
8/23/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:NPHC
CIK
1119643
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.05 million
Net Margins
-2,277.73%
Pretax Margin
-2,277.73%
Return on Equity
N/A
Return on Assets
-317.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.02
Quick Ratio
0.03

Sales & Book Value

Annual Sales
$380 thousand
Price / Sales
1.88
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
7,159,740,000
Free Float
2,756,500,000
Market Cap
$715.97 thousand
Optionable
Not Optionable
Beta
0.94
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (OTCMKTS:NPHC) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners